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Context-dependent inhibition of N-methyl-D-aspartate (NMDA) receptors has important
therapeutic implications for the treatment of neurological diseases that are associated with
altered neuronal ﬁring and signaling. This is especially true in stroke, where the proton
concentration in the afﬂicted area can increase by an order of magnitude. A class of allosteric
inhibitors, the 93-series, shows greater potency against GluN1-GluN2B NMDA receptors in
such low pH environments, allowing targeted therapy only within the ischemic region. Here
we map the 93-series compound binding site in the GluN1-GluN2B NMDA receptor amino
terminal domain and show that the interaction of the N-alkyl group with a hydrophobic cage
of the binding site is critical for pH-dependent inhibition. Mutation of residues in the
hydrophobic cage alters pH-dependent potency, and remarkably, can convert inhibitors into
potentiators. Our study provides a foundation for the development of highly speciﬁc neu-
roprotective compounds for the treatment of neurological diseases.
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In the ischemic environment induced by stroke, the pH of theafﬂicted area can drop dramatically from 7.4 to as low as 6.5 asa result of altered metabolism and the concurrent buildup of
carbon dioxide due to reduced tissue perfusion1–4. The extra-
cellular pH falls during ischemia and traumatic brain injury,
which also triggers glutamate release by a variety of mechanisms,
resulting in hyperactivity of N-methyl-D-aspartate (NMDA)
receptors. Overactive NMDA receptor-mediated cation entry into
the neuron leads to neuronal death1,5, a process often referred to
as excitotoxicity6. The NMDA receptor is a ligand-gated ion
channel with key roles in learning and memory and has also been
implicated in a number of neurological diseases and disorders,
including schizophrenia7, epilepsy8, and depression9. The
majority of NMDA receptors reside in the cell membrane as a
heterotetramer consisting of two GluN1 subunits with a and b
isoforms determined by an alternatively spliced exon 5, and two
GluN2 subunits, of which there are four different subtypes
(GluN2A–D)10. Three structured domains comprise the intact
NMDA receptor: the regulatory amino-terminal domain (ATD),
the ligand-binding domain (LBD), and the channel-forming
transmembrane domain (TMD)11–15.
Subtype-selective small-molecule inhibitors of the NMDA
receptor are desirable, as they can effectively reduce excito-
toxicity during ischemia in preclinical models (see Table S2 in
ref. 4). Previous studies have suggested that GluN2B-containing
NMDA receptors can more effectively cause excitotoxic neu-
ronal death compared to GluN2A-containing NMDA recep-
tors16,17, highlighting the relevance of targeting GluN2B-
containing NMDA receptors as a potential therapeutic strat-
egy for ischemic injuries. A wide array of competitive antago-
nists have been described that bind at the LBD18–22, but this
domain bears high sequence identity among all of the
glutamate-binding GluN2 subunits, which could potentially
allow for non-speciﬁc effects through block of all NMDA
receptors10,23. The composition of the ATD, by contrast, is
highly divergent among the GluN2 subtypes, and is therefore an
attractive target for subtype-speciﬁc negative allosteric mod-
ulation23,24; indeed, the phenylethanolamine class of allosteric
NMDA receptor inhibitors, which includes the iconic com-
pounds ifenprodil, eliprodil, and the closely related acetamide
radiprodil, bind speciﬁcally to the GluN1–GluN2B ATD het-
erodimer interface in GluN2B-containing NMDA receptors25.
Recent structural work has shown that these small molecules
physically cannot be accommodated within the
GluN1–GluN2A ATD heterodimeric interface in GluN2A-
containing NMDA receptors26.
The development of allosteric inhibitors that exert a stronger
inhibitory effect at low pH have been shown to be neuropro-
tective during ischemic events27, and a novel class of GluN2B-
speciﬁc compounds referred to as the 93-series exhibit highly
pH-dependent inhibition of NMDA receptors4,28, but until now
the underlying molecular basis for this effect was unknown. In
order to better understand the context-dependence of these
compounds as a means to designing effective therapeutics, we
employ X-ray crystallography, isothermal titration calorimetry
(ITC), and two-electrode voltage clamp (TEVC) electro-
physiology to determine where and how this class of inhibitors
binds to the NMDA receptor. Here, we show that the pH-
dependent inhibitory effect of the 93-series compounds is partly
attributed to direct binding to the GluN1b–GluN2B hetero-
dimeric interface and that the placement of the N-alkyl group to
the sub-pocket which we name the hydrophobic cage is critical
for pH-dependency. Extensive site-directed mutagenesis indicate
that the protonation state of a histidine residue in the
hydrophobic cage controls the strength of hydrophobic interac-
tions with the N-alkyl group.
Results
pH-sensitive binding afﬁnity of the 93-series. The 93-series
compounds are allosteric inhibitors of GluN1–GluN2B NMDA
receptors, which bind to the GluN1–GluN2B subunit interface
within the ATD. These compounds were designed based on the
propanolamine AM-92016 and show up to 10-fold higher
potency at pH 6.9 as compared to pH 7.6 (refs. 4,28). We focused
on a subset of the 93-series compounds with systematic structural
diversity, ranging from an unsubstituted analog to an N-butyl
substitution (Fig. 1a). Yuan et al.4 recently demonstrated that the
N-butyl substitution, 93-31, showed a large pH-induced potency
enhancement, which they referred to as the pH-boost and which
we conﬁrmed using TEVC recordings in Xenopus laevis oocytes
(Fig. 1b). 93-31 at half-maximal inhibitory concentrations did not
alter glutamate potency at pH 7.6 or 6.9, eliminating reduced
activation by glutamate as a potential component of pH sensi-
tivity (Supplementary Figure 1a). The IC50 values for 93-31
inhibition of exon 5-lacking GluN1a–GluN2B receptors shifted
from 1.7 ± 0.38 μM at pH 7.6 to 0.23 ± 0.05 μM at pH 6.9—a pH-
boost of 7.4 per half log change in extracellular pH (Fig. 1c;
Table 2). IC50 values were virtually identical for exon 5-
containing GluN1b–GluN2B receptors and showed a pH-boost
of 9.4 from 1.7 ± 0.26 μM at pH 7.6 to 0.18 ± 0.05 μM at pH 6.9
(n= 9), suggesting the inclusion of exon 5 does not inﬂuence pH
sensitivity of this class of modulators (Supplementary Figure 1b).
This observation is consistent with the previous ﬁnding that the
location of the exon 5-encoded motif is at the domain interface
between the ATD and the LBD in the intact NMDA receptors29,
which is too far away from the allosteric inhibitor-binding site to
have any physical impact on inhibitor binding25.
In order to directly estimate binding afﬁnities of these
inhibitors for their binding site in the GluN1–GluN2B NMDA
receptors, we performed ITC using the puriﬁed GluN1a–GluN2B
ATD proteins titrated with ligands of various N-substituent
lengths at pH 7.6 and pH 6.5 to mimic the extreme drop in pH
that can occur at the ischemic core1–4 (Fig. 2a, b; Supplementary
Figures 2 and 3). Toward this end, we expressed the isolated rat
GluN1a–GluN2B ATD heterodimer proteins in GnTI− HEK293S
cells. Here, for clarity we will call the GluN1 ATD with and
without exon 5 GluN1b ATD and GluN1a ATD, respectively. For
all of the compounds tested, the ITC experiments unambiguously
detected heat exchange when they are injected into the ATD
protein samples (Fig. 2). As expected, ifenprodil, which does
not have an analogous N-alkyl substitution, did not exhibit
a detectable pH-dependent binding afﬁnity, with a KD of
226 ± 15 nM at pH 7.6 and a KD of 249 ± 16 nM at pH 6.5,
corresponding to a negligible pH-boost (Fig. 2c; Table 1).
Consistent with the previous report4, several of the 93-series
compounds with relatively small N-alkyl substitutions also
showed negligible differences in binding afﬁnities, including the
unsubstituted 93-4, N-ethyl 93-5, N-propyl 93-6, and N-isopropyl
93-115 (Figs. 1a and 2c, d). Indeed, not until the volume of the N-
alkyl substituent is greater than a propyl substitution (approxi-
mately 50 Å3) does the pH-sensitive binding afﬁnity become
apparent, rapidly increasing to induce a pH-boost of 1.6 for the
N-butyl 93-31 and 2.1 for N-methylpropyl 93-97 (Fig. 2d;
Table 1).
Structure of the ATD heterodimer bound to the 93-series. As a
means to better understand the precise molecular interactions
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taking place between the ATD and the inhibitory ligands, we
obtained X-ray crystallographic structures of the 93-series
compounds bound to the GluN1–GluN2B ATD heterodimer.
Despite exhaustive efforts, we were not able to consistently
produce high-quality crystals of the GluN1a–GluN2B ATD
complex; we therefore revisited and improved our previous
method to use the Xenopus GluN1b ATD and rat GluN2B
ATD25, since this splice variants showed identical potency
and pH sensitivity as GluN1a. As described in Methods, we
were able to streamline and optimize our puriﬁcation and
crystallization conditions in order to reliably produce large
crystals of the GluN1b–GluN2B inhibitor complex which
routinely diffracted considerably better than in previous
studies25,30, up to 2.1 Å (Supplementary Table 1); ITC
experiments conﬁrmed that the two constructs have nearly
identical binding properties for ifenprodil (Table 1; Supple-
mentary Figure 4). All of the crystal structures showed
unambiguous density for the GluN1b and GluN2B ATD
proteins as well as the tested ligands at the inter-subunit
interface of the GluN1b–GluN2B ATD heterodimers (Sup-
plementary Figures 5 and 6). The structure of the
GluN1b–GluN2B ATD heterodimers is superimposable to
that of the GluN1a–GluN2B ATD heterodimers within the
GluN1a–GluN2B heterotetrameric NMDA receptor channel
as shown previously11. Furthermore, the 21 residues encoded
by exon 5 in GluN1b are distantly located from the allosteric
modulator binding sites. Thus, the structural information of
the compound binding site obtained in GluN1b–GluN2B
ATD is equivalent to that in the GluN1a–GluN2B ATD25,
consistent with our functional data showing identical sensi-
tivity of both splice variants to 93-31 at all pH values tested.
The binding site of the 93-series compounds overlays closely
with the canonical phenylethanolamine-binding site at the
GluN1b–GluN2B subunit interface (Fig. 3a–e). However, the
binding mode is quite different, as the backbone of the 93-series
ligands adopts a unique “Y-shaped” conformation compared to
the more linear arrangement of ifenprodil (Fig. 3f). Furthermore,
the binding mode of the NMDA receptor inhibitor EVT-101
(ref. 30) overlaps with the positioning of the 93-series dichlor-
ophenyl group and the N-alkyl group (Fig. 3g). This series
therefore appears to be the ﬁrst that captures all interactions
observed in the three parts of the ifenprodil pocket, in that it
overlaps both with ifenprodil and EVT-101. The alkyl-substituted
amine of the 93-series compounds forms a hydrogen bond with
GluN2B(Gln110), while the dichlorophenyl group is favorably
positioned to form hydrophobic contacts with GluN1b(Phe113),
GluN2B(Pro177), GluN2B(Ile111), and GluN2B(Phe114) (Fig. 3d,
e). The arylsulfonamide group lies at the opposite end of the
binding pocket, where it forms hydrogen bonds with GluN2B
(Glu236) and with the backbone amides of GluN2B(Met207) and
GluN2B(Ser208) (Fig. 3d, e). The N-alkyl substitution of the 93-
series compounds branches into the extended binding site and
forms van der Waals interactions with GluN1b(Tyr109), GluN1b
(Ile133), GluN2B(Met134), and GluN2B(Pro177) (Figs. 3e and
4a). The extent of the van der Waals contacts in this site depends
on the orientation and the size of the N-alkyl group of the 93-
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Fig. 1 pH-sensitive negative allosteric modulators of GluN2B-containing NMDA receptors. a The 93-series compounds28 are shown together with the
phenylethanolamine ifenprodil and EVT-101. b Representative TEVC recordings of wild-type GluN1-4a/GluN2B NMDA receptors in Xenopus oocytes are
shown in response to maximally effective concentration of glutamate and glycine (100 and 30 μM, respectively). When normalized to the maximal
response, recordings at pH 6.9 showed substantially higher potency of 93-31 than at pH 7.6. c Concentration–response curves from TEVC experiments at
pH 7.6 (gray) and 6.9 (black) for inhibition of wild-type GluN1-4a/GluN2B NMDA receptor by 93-31 (also see Table 2). Symbols and error bars represent
mean ± S.E.M.; the number of replicates is listed in Table 2
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series compounds. Among all of the 93-series compounds tested,
the N-butyl group of 93-31 most closely matches the shape of the
hydrophobic cage by aligning in such a way as to form a
hydrophobic contact with the side chain of GluN1b(Ile133)
(Supplementary Figure 7).
These binding modes are consistent with many of the trends
that appear in our ITC data. The unsubstituted variant 93-4 has a
weaker KD at high and low pH than the N-methyl 93-5, N-propyl
93-6, and N-butyl 93-31 variants because it lacks the aliphatic
substituent required to interact with the protein residues in the
extended binding site. As the N-alkyl substituent grows to the size
of N-butyl, it is ﬁnally long enough to form these additional
interactions to allow for tighter binding at the extended site. This
is reﬂected in higher afﬁnities than with the unsubstituted 93-4, as
well as ifenprodil (Table 1). The branched N-methylethyl 93-115
and N-methylpropyl 93-97 variants, which do not have a larger
volume than the N-butyl compound, likely suffer from steric
constraints not encountered by the higher-afﬁnity unbranched
93-31. All three compounds tested which had sufﬁcient N-alkyl
volumes to ﬁll the extended binding site (93-31, 93-88, and 93-97)
showed a considerable pH-boost when measured by ITC. N-
methylpropyl (93-97) shows a large boost with respect to pH but
weaker absolute binding afﬁnity than 93-31, again, possibly due
to steric obstruction. The compound 93-88 is N-butyl substituted
like 93-31 and also shows a pH-boost; however, as the (R)
enantiomer, 93-88 must adopt quite a different binding pose in
order to form the hydrogen bond to GluN2B(Gln110), which in
turn contorts the molecule into an unfavorable orientation and
reduces binding afﬁnity (Supplementary Figures 6 and 7). These
data allow us to interrogate one component—ligand binding to
the isolated ATD heterodimer—of the complex pH-dependence
of these inhibitors, which may also include pH-dependent
changes in the conformations of the full-length protein.
Functional characterization of the 93-series binding pocket. To
validate the unique binding mode of the 93-series compounds
observed in our crystallographic studies and to gain mechanistic
insights into the pH sensitivity of the 93-31, we conducted site-
directed mutagenesis of residues around the binding pocket and
measured the ion channel activity by TEVC recordings in
Xenopus oocytes. Toward this end, we obtained
concentration–response curves of 93-31 at pH 6.9 and pH 7.6 on
the mutant GluN1-4a-GluN2B NMDA receptors. We ﬁrst
examined a potential role for the arylsulfonamide group of the
93-series compounds in facilitating pH sensitivity, which interacts
with GluN2B(Glu236) (Fig. 3d, e). Although the pKa of similar
arylsulfonamide groups31,32 are often between 6 and 7, analytical
evaluation determined the pKa to be 8.0, suggesting only a
modest change of the concentration of protonated sulfonamide
from 72% at pH 7.6 to 93% at pH 6.9, a shift of 1.3-fold. Any
potential change in the ionization of the sulfonamide nitrogen
itself as the pH drops from 7.6 to 6.9 might change the nature of
the interaction between the ligand and GluN2B(Glu236). How-
ever, consistent with the minimal change in ionization of the
sulfonamide given the measured pKa value, changing the charge
of the Glu236 side chain in GluN2B(Glu236Gln) produced no
substantial change in IC50 or efﬁcacy of 93-31 inhibition at either
pH 6.9 or pH 7.6 as compared to the wild type (Fig. 4c; Table 2).
These data conﬁrm that the GluN2B(Glu236)-sulfonamide
interaction does not contribute to the pH-sensitive effect.
As pH sensitivity appears to be a function of 93-series N-
substituent volume, we next tested residues in the immediate
vicinity of the N-alkyl group within the protein hydrophobic
cage. As described above, our crystal structures clearly identiﬁed
GluN1b(Ile133) as the major interacting residue with the N-alkyl
group of the 93-series compounds, and the strength of van der
Waals interactions with GluN1b(Ile133) will vary depending on
the nature of the N-alkyl substituent (Fig. 4a, b; Supplementary
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Figure 7). The GluN1b(Ile133Ala) mutation, which decreases the
volume of the hydrophobic side chain, consistently reduces both
potency and efﬁcacy of inhibition by 93-31 as well as the pH-
boost (Fig. 4d; Table 2). The placement of the N-alkyl substituent
is also likely to be stabilized by the side chain of GluN2B(Met134)
and GluN2B(Pro177), which are located within 5 Å of the N-alkyl
group. The GluN2B(Met134Ala) mutation does not affect
potency, but increases the current at pH 6.9 (36%) and reduces
pH-boost (3.2-fold). The GluN2B(Pro177Gly) mutation had a
robust effect on potency, efﬁcacy, and pH-boost (Fig. 4e, f;
Table 2).
Finally, the hydrophilic residue sitting at the edge of the pocket,
GluN2B(Asp136) (Fig. 4a, b), is not directly interacting with the
N-alkyl group. Reduction of hydrophilicity by the GluN2B
(Asp136Ala) mutation had a minor increase in pH-boost with
minimal changes in potency and efﬁcacy, perhaps reﬂecting
slightly favored positioning of the N-alkyl group in the pocket
(Fig. 4g; Table 2). Overall, the above mutagenesis studies indicate
that all of the residues contributing to hydrophobic interactions
with the N-alkyl group of the 93-31 are involved in controlling
efﬁcacy, potency, and pH-boost.
Because the chemistry of pH sensitivity typically involves
changes in protonation states associated with altered solution pH,
we speculated that the hydrophobic interaction involving the N-
alkyl group of the 93-series compounds is controlled by the
protonation of residues near the hydrophobic pocket. One such
residue that caught our attention was GluN1b(His134), which is
positioned to form a hydrophobic interaction with GluN1b
(Ile133) when it is not protonated (Fig. 4b). When protonated at
low pH, GluN1b(His134) has a considerably weaker hydrophobic
interaction with GluN1b(Ile133), which in turn allows GluN1b
(Ile133) to form stronger interactions with the N-alkyl group of
the 93-series compounds and serve as a local pH sensor. GluN1b
(His134) is located at the exit of the GluN1b–GluN2B subunit
interface and is solvent accessible, allowing it to sense solution
pH. The pKa of His is 6 in free solution, and likely different in the
context of adjacent residues. Thus, the His134 pKa could be tuned
to show a maximal change in the ionization state with changes in
extracellular pH. For example, a pKa of 6.4 would yield a four-
fold change and a pKa of 6.8 would yield a three-fold change in
the ionization state of His134 with a change in extracellular pH
from 7.6 to 6.9. Further supporting the important role of the
protonation state of GluN1(His134) is the observation that
breakage of the GluN1(His134)–GluN1(Ser108) interaction by
mutating GluN1(Ser108Ala) robustly reduces 93-31 potency,
efﬁcacy, and pH-boost (Fig. 4i; Table 2). Situated in the middle of
these pH-sensitive elements is GluN1(Tyr109), proximal to the
backbone and the N-alkyl group of the 93-series compounds. The
GluN1(Tyr109Ala) mutation to remove the bulky side chain
mildly lowers potency and efﬁcacy of inhibition, but not pH-
boost (Table 2).
We tested the GluN1a(His134Ala) mutation4 prior to our
current crystallographic studies and not only observed elimina-
tion of pH-boost (as predicted with the loss of ionizeable side
chain), but also the conversion of 93-31 from an inhibitor to a
potentiator (Fig. 4h; Table 3). A similar potentiating effect of the
GluN1a(His134Ala) mutation was observed for 93-5, whereas we
observed only a minor effect for ifenprodil (Supplementary
Figure 8a, b), indicating that the potentiating effect is facilitated
by the N-alkyl group of the 93-series compounds. GluN1b
(His134) is thus a critical regulator of pH-sensitive compound
binding and allosteric inhibition in general. Analogous to
mutations at His134, we observed that substituting a bulkier
group for GluN1(Tyr109Trp) likely disrupted the local architec-
ture of the pH-sensitive elements, and had a similar effect to the
GluN1 (His134Ala) mutation, in that binding of 93-31 and 93-5
results in potentiation rather than inhibition. As in the case of
GluN1 (His134Ala), only minor potentiation was observed for
ifenprodil, conﬁrming the role of the 93-series N-alkyl group in
this effect. Neither of these potentiating mutations altered the
receptor’s sensitivity to extracellular protons (Supplementary
Figure 8e, f; Table 4), indicating that the potentiation does not
involve a change in tonic proton inhibition. This indicates that
the architecture of the binding pocket for the N-alkyl group and
its vicinity is uniquely organized to mediate pH-sensitive
compound binding. Furthermore, the area around GluN1
(His134) is a local pH sensor that can potentially be manipulated
in order to develop pH-dependent positive and negative allosteric
modulators (Fig. 4h; Supplementary Figure 8c; Table 3).
Discussion
Our work here has identiﬁed a ligand-binding mode speciﬁc to
GluN2B-containing NMDA receptors that encompasses and
expands the canonical phenylethanolamine-binding pocket25,30.
The 93-series compounds occupy the ifenprodil pocket and also
uniquely ﬁll a hydrophobic pocket that branches out from the
phenylethanolamine-binding site, thereby introducing a greater
Table 1 Results of ITC experiments titrating the ATD dimer with various ligands
Ligand Ifenprodil
(GluN1a–GluN2B)
Ifenprodil
(GluN1b–GluN2B)
93-4 93-5 93-6 93-115 93-31 93-88 93-97
N-substituent
volume (Å3)
(n/a) (n/a) 0.97 33.74 50.54 50.33 67.35 67.35 67.13
npH 7.6 1.0 ± 0.01 0.98 ± 0.01 0.98 ± 0.02 1.00 ± 0.01 1.0 ± 0.01 1.0 ± 0.01 0.95 ± 0.01 0.99 ± 0.02 1.0 ± 0.02
npH 6.5 0.97 ± 0.01 – 0.98 ± 0.01 0.98 ± 0.01 1.0 ± 0.01 1.0 ± 0.01 1.0 ± 0.01 1.00 ± 0.02 0.99 ± 0.02
KDpH 7.6 (nM) 226 ± 15 255 ± 11 147 ± 5.0 66.3 ± 3.2 129 ± 9.3 175 ± 5.6 121 ± 5.1 331 ± 29 305 ± 18
KDpH 6.5 (nM) 249 ± 16 – 170 ± 4.8 70.7 ± 2.0 116 ± 2.2 186 ± 11 78 ± 3.0 171 ± 6.6 147 ± 5.6
ΔHpH 7.6 (kcal
mol−1)
−1.53 × 104 ± 346 −1.48 × 104 ± 265 −2.37 ×
104 ± 457
−2.28 ×
104 ± 834
−1.94 ×
104 ± 809
−2.38 ×
104 ± 708
−2.16 ×
104 ± 944
−2.79 × 104
± 765
−2.12 ×
104 ± 568
ΔHpH 6.5 (kcal
mol−1)
−1.70 × 104 ± 982 – −2.24 ×
104 ± 483
−2.11 × 104
± 1140
−1.96 ×
104 ± 146
−2.09 ×
104 ± 568
−2.22 ×
104 ± 807
−2.03 × 104
± 1430
−1.75 ×
104 ± 941
TΔSpH 7.6 (kcal
mol−1)
−6.10 × 103 ± 308 −5.64 × 104 ± 264 −1.42 ×
103 ± 447
−1.28 ×
104 ± 866
−9.87 ×
103 ± 804
−1.41 × 104
± 536
−1.19 × 104
± 914
−1.89 × 104
± 804
−1.22 ×
104 ± 544
TΔSpH 6.5 (kcal
mol−1)
−7.84 × 103 ± 960 – −1.30 ×
103 ± 500
−1.12 × 104
± 1140
−9.92 ×
103 ± 132
−1.16 × 104
± 604
−1.23 ×
104 ± 811
−1.09 × 104
± 1440
−8.00 ×
103 ± 919
pH-boost 0.91 ± 0.066 – 0.86 ±
0.030
0.94 ±
0.047
1.11 ± 0.081 0.94 ±
0.034
1.55 ±
0.067
1.93 ± 0.168 2.08 ±
0.125
Respective ligands were titrated into the GluN1a–GluN2B ATD heterodimer. Superscript indicates the pH at which the experiments were performed to generate the given value. pH-boost is the ratio of
KDpH 7.6 to KDpH 6.5. The isolated GluN1a–GluN2B ATD expressed in HEK cells was used for all ITC experiments, except for one set of experiments in which we titrated ifenprodil into the isolated
GluN1b–GluN2B ATD used for crystallization. Values are presented as mean ± S.E.M. All experiments were performed in triplicate as described in Methods. Side chain volumes were calculated using
MolInspiration (molinspiration.com). n/a not applicable
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number of protein–ligand contacts and thus more options for
rational drug design. In this manner, 93-31 is the ﬁrst ligand to
occupy all three elements of the negative allosteric modulatory
site within the GluN1–GluN2B ATD heterodimer. Our data also
suggest that the 93-series compounds that possess an N-alkyl
group that matches the size and shape of the hydrophobic pocket
exert allosteric inhibition with substantial pH-dependence. Our
ITC experiments demonstrated that the isolated GluN1–GluN2B
ATD heterodimer alone shows a pH-boost, although the mag-
nitude of the effect is modest compared to that observed for full-
length receptors in TEVC recordings. This difference in the
extent of pH-boost may be attributed to the fact that our ITC
experiments were conducted on the isolated GluN1–GluN2B
ATD heterodimer, whereas TEVC was performed using intact
channels that contain two GluN1–GluN2B ATD heterodimers
per heteroterameric assembly. We interpret the difference as
suggesting that some portion of the pH-boost occurs at the level
of compound binding to the ATD but a substantial portion of the
effect occurs through downstream effects perhaps involving
conformational alteration in both the LBD and ATD regions14,33.
Taken together, our experiments demonstrate that the hydro-
phobic interactions involving the 93-series N-alkyl group are
critical to mediating allosteric inhibition in a pH-dependent
manner. We predict that the potency and efﬁcacy of inhibition, as
well as pH-boost, of the 93-series compounds could be improved
by replacing the N-alkyl group with a more extended hydro-
phobic group, for example, N-aryl, to potentially strengthen
hydrophobic interactions with GluN1 (Ile133), GluN2B(Pro177),
and GluN2B(Met207).
The structural basis for the pH-sensitive binding of the 93-
series compounds may involve GluN1(His134), which is situated
next to GluN1(Ile133) and forms a hydrophobic interaction when
not protonated at high pH. At lower pH values (higher proton
concentrations), however, the interaction between GluN1(Ile133)
and GluN1(His134) likely weakens as an increased proportion of
GluN1(His134) is protonated. This would be predicted to
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Fig. 3 Structure of the 93-series binding site. a The intact heterotetrameric GluN1b/GluN2B NMDA receptor34 is composed of three structured domains,
with the ATD furthest from the cell membrane (PDB code: 6CNA). b, c The crystal structure of the isolated GluN1b/GluN2B ATD heterodimer bound to the
pH-sensitive 93-31 reveals the ligand-binding site at the heterodimer interface, as viewed from two angles. d, e The key residues surrounding the N-alkyl
chain of 93-31 are primarily hydrophobic, shown here in stereo view. f Overlay of 93-31 and ifenprodil25 (yellow, PDB code: 3QEL). g Overlay of 93-31 and
EVT-101 (ref. 29) (green, PDB code: 5EWM)
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strengthen the van der Waals contacts between the N-alkyl group
of the 93-series compounds and GluN1(Ile133).
The GluN1 (His134Ala) mutation4 not only abolishes the pH-
boost but also converts 93-31 and 93-5 into strong potentiators,
while only blocking the inhibitory action of ifenprodil. We
observed an even greater effect when GluN1(Tyr109)—located
next to GluN1(Ile133) and GluN1(His134)—was mutated to a
larger tryptophan in order to perturb the positioning of those
residues, implying that GluN1(Tyr109), GluN1(Ile133), and
GluN1(His134) constitute a local hub that can inﬂuence both the
binding and downstream action of negative allosteric modulators
that bind to the ATD heterodimer interface in GluN1–GluN2B
NMDA receptors. The opening and closing of the bi-lobe struc-
ture of GluN2B ATD and rearrangement of the GluN1–GluN2B
subunit interface at the ATD is coupled to activation and allos-
teric inhibition of the GluN1–GluN2B NMDA receptors14. The
above residues in the hydrophobic cage are located in proximity
to the subunit interface, thus are in the ideal position to control
the activity of the GluN1–GluN2B NMDA receptors. The
potentiating effect of 93-31 and 93-5 on the GluN1(Tyr109Trp)
and GluN1(His134Ala) mutants perhaps involves rearrangement
of the ATD heterodimers in a way to favor activation, which lead
to the tantalizing possibility that GluN2B-speciﬁc positive allos-
teric modulators could be developed. Such modulators could have
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Fig. 4 TEVC concentration–response curves for GluN1-4a–GluN2B mutants. a The N-alkyl group of 93-31 is accommodated by the “hydrophobic cage” as
shown by the hydrophobic (red) to non-hydrophobic (white) surface presentation. b Key residues at the GluN1/GluN2B ATD dimer interface that interact
with the N-alkyl chain of 93-31 were mutated and evaluated for effects on pH sensitivity of 93-31. c–i Current responses to maximally effective
concentration of glutamate and glycine (100 μM glutamate, 30 μM glycine) are shown in the presence of varying concentrations of 93-31 as a proportion of
maximal response. Experiments conducted at pH 7.6 are shown in gray; experiments at pH 6.9 are shown in black. h, j Two mutations, GluN1-4a
(His134Ala) and GluN1-4a(Tyr109Trp), convert 93-31 into a potentiator. Experiments here were performed at pH 7.6 (gray), with the wild-type curve
displayed for comparison (black). Error bars represent mean ± S.E.M. See Tables 2 and 3 for ﬁtted IC50 values and the number of independent replicates
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therapeutic potential in diseases characterized by NMDA receptor
hypofunction, such as schizophrenia34,35. Overall, our study
shows that by modifying a speciﬁc site on this class of ligands
within the parameters we have established here, there is great
potential for the development of highly targeted therapeutics for
neurological diseases.
Methods
Materials. All 93-series compounds were synthesized as described elsewhere28,
and puriﬁed to >95% purity. 93-series compounds in this study correspond to the
following compounds in Tahirovic et al.28: 93-4 is compound 29, 93-5 is compound
67, 93-6 is compound 69, 93-31 is compound 70, 93-88 is compound 106, 93-97 is
compound 72, and 93-115 is compound 74. All starting materials and other che-
micals were from Sigma unless otherwise indicated. Ifenprodil hemitartrate was
purchased from Tocris (#0545).
Determination of pKa. The pKa values for 93-31 were determined using the
spectrometric (UV-metric) technique (Pion Inc., East Sussex, UK, RH18 5DW).
93-31 was titrated in three UV-metric single titrations on SiriusT310026 from pH
12.5–1.5 at concentrations of 62–51 μM, under methanol–water co-solvent con-
ditions (the methanol mixing ratio varied from 60.8 to 34.7% w/w). No pre-
cipitation of the sample from solution was observed and two pKa values, with
aqueous values of 8.0 ± 0.03 and 9.5 ± 0.01, were determined from the spectro-
scopic data collected by Yasuda–Shedlovsky extrapolation of the individual results
obtained36–38.
Crystallization of the ATD heterodimer. Coexpression and puriﬁcation of the
Xenopus GluN1b and rat GluN2B ATD heterodimer were performed as described
previously25. Brieﬂy, Trichoplusia ni (High Five, Thermo Fisher) insect cells were
infected with a baculovirus harboring both Xenopus GluN1b ATD and rat GluN2B
ATD for 48 h. The concentrated medium was subjected to puriﬁcation by metal
afﬁnity resin (GE Lifesciences) charged with CoCl2. Poly-Histidine tags at the C-
terminus of GluN1b ATD and the N-terminus of the GluN2B ATD were removed
by thrombin digestion and the digested samples were further puriﬁed by Super-
dex200 (GE Lifescience). Puriﬁed protein was concentrated to 10 mgmL−1 and
dialyzed against 50 mM NaCl, 10 mM Tris (pH 8.0), and 10 μM ifenprodil hemi-
tartrate (Tocris). Crucially, we found it to be absolutely necessary to ﬁlter the
dialyzed protein through a 0.1 μm spin ﬁlter (Millipore) just before setting up
crystal screens. Crystals grew in sodium formate/HEPES as in our previous study25,
initially appearing after 3–4 days, then continuing to grow for up to 2–3 weeks at
18 °C. Crystals were transferred to 2 μL drops containing 4 M sodium formate, 0.1
M HEPES (pH 7.5), 35 mM NaCl, 7 mM Tris (pH 8.0), and 50 μM of the respective
inhibitors, and allowed to soak overnight. Crystals were then transferred to a new
drop of the same condition and soaked overnight again. In order to gradually
increase the concentration of sodium formate for use as a cryoprotectant, these
crystals were further transferred to a fresh drop of the same condition but with 4.5
M sodium formate, soaked overnight, and then transferred again to the same
condition with 5.0 M sodium formate for a ﬁnal overnight soak. In combination
with the critical protein ﬁltration step, this multi-day gradual soaking protocol was
essential to improving crystal diffraction. Crystals were ﬂash-frozen in liquid
nitrogen for X-ray diffraction data collection.
Preparation of the GluN1a–GluN2B ATD fusion proteins. To efﬁciently express
the ATD domains of Xenopus GluN1a and rat GluN2B, we used the alkaline
phosphatase secretion signal and fused the two domains with a 57 residue linker as
described elsewhere26, with the following modiﬁcations: due to an intrinsic
thrombin site in the GluN2B ATD, we engineering Tobacco Etch Virus (TEV)
protease sites into this construct to remove the linker. In addition, three glycosy-
lation sites were removed by mutating GluN1a Asn61 and Asn371 to Gln, and
GluN2B Asn348 was mutated to Asp.
Suspension cell cultures of HEK 293 S GnTI− cells (ATCC #3022) were grown
in JMEM (VWR), which was modiﬁed to include 20% FreeStyle 293 expression
media (Gibco), 2.5% FBS, 2.5 mM GlutaMAX (Gibco), 0.3% Primatone, 0.1%
Pluronic F68, 20 mM HEPES pH 7.5, and 2 g/L sodium bicarbonate. Cell
cultures were maintained at 37 °C with 5% CO2 and grown to a density of
Table 2 Results of TEVC 93-31 concentration–response
experiments with GluN1-4a/GluN2B mutants
pH 7.6 pH 6.9
Constructs IC50 (μM), %
responsea
nH (n)
IC50 (μM), %
responseb
nH (n)
IC50 (pH 7.6)/
IC50 (pH 6.9)
GluN1-4a/GluN2B
(WT)
1.7 ± 0.38, 34%
nH 0.7 (24)
0.23 ± 0.05, 18%
nH 0.7 (23)
7.4
GluN1-4b/GluN2B
(WT)
1.7 ± 0.26, 46%
nH 1.3 (9)
0.18 ± 0.05, 22%
nH 1.0 (9)
9.4
GluN1-4a(S108A) 30 ± 12, 69%
nH ND (7)
20 ± 4.7, 62%
nH ND (5)
1.5
GluN1-4a(Y109A) 6.2 ± 3.0, 45%
nH 0.6 (6)
0.80 ± 0.30, 28%
nH 0.6 (5)
7.6
GluN1-4a(Y109W) 1.4 ± 0.37, 186%c
nH 1.0 (7)
0.94 ± 0.19, 212%c
nH 0.8 (8)
1.5
GluN1-4a(I133A) 6.3 ± 2.7, 51%
nH ND (6)
1.2 ± 0.42, 41%
nH 0.4 (7)
5.3
GluN2B(M134A) 1.1 ± 0.44, 36%
nH 0.4 (8)
0.38 ± 0.08, 36%
nH 0.4 (8)
2.9
GluN2B(D136A) 3.8 ± 1.5, 44%
nH 0.8 (6)
0.36 ± 0.09, 24%
nH 0.6 (6)
11
GluN2B(P177A) 38 ± 9.7, 73%
nH ND (6)
5.7 ± 1.2, 56%
nH ND (4)
6.7
GluN2B(P177G) 4.7 ± 0.54, 60%
nH ND (9)
2.3 ± 0.57, 45%
nH 0.7 (7)
2.0
GluN2B(E236A) 3.2 ± 1.2, 41%
nH 0.7 (10)
0.49 ± 0.10, 22%
nH 0.7 (8)
6.5
GluN2B(E236Q) 5.2 ± 0.73, 59%
nH ND (8)
0.73 ± 0.17, 28%
nH 0.6 (6)
7.1
Concentration–response curves were generated in the presence of 100 μM glutamate and 30
μM glycine, and the listed ligands, and normalized against current from glutamate and glycine
alone. IC50 values are given ± S.E.M. (n): number of independent replicates. In all of the
recordings, Hill coefﬁcient (nH) ranged from 0.4 to1.3, and were not determined when the
inhibition was less than 50% at the highest concentrations tested. ND not determined
aThe steady-state response was determined as a percentage of the current at 3 μM 93-31, pH
7.6
bThe steady-state response was determined as a percentage of the current at 3 μM 93-31, pH
6.9
cThe GluN1-4a (Y109W) mutant converted 93-series ligands into potentiators; EC50 value and
maximal potentiation given
Table 3 Results of TEVC concentration–response experiments with GluN1-4a/GluN2B potentiating mutants
Constructs 93-31 pH 7.6
IC50 (μM), % response
nH (n)
93-5 pH 7.6
IC50 (μM), % response
nH (n)
Ifenprodil, pH 7.6
IC50 (μM), % response
nH (n)
GluN1-4a/GluN2B (WT)b 1.2 ± 0.46, 34%a
nH 0.8 (6)
0.12 ± 0.01, 39%c
nH 0.6 (5)
0.12 ± 0.02, 35%d
nH 1.0 (7)
GluN1-4a(Y109W)b 1.3 ± 0.28, 177%e
nH 1.0 (8)
0.52 ± 0.20, 265%e
nH 0.9 (7)
ND, 115%f
nH ND (9)
GluN1-4a(H134A)b 1.8 ± 0.23, 153%e
nH 1.1 (6)
0.32 ± 0.08, 140%e
nH 0.7 (6)
ND, 105%f
nH ND (9)
Concentration–response curves were generated in the presence of 100 μM glutamate and 30 μM glycine, and the listed ligands, and normalized against current from glutamate and glycine alone. IC50
values are given ± S.E.M. (n): number of independent replicates. In all of the recordings, Hill coefﬁcient (nH) ranged from 0.6 to 1.1, and were not determined when the potentiation was less than 30% at
the highest concentrations tested. ND not determined
aThe steady-state response was determined as a percentage of the current at 3 μM 93-31, pH 7.6
bTo prevent run-down of current, experiments in the second table (WT, Y109W, and H134A) were conducted in oocytes co-injected with 13 nL of 100mM BAPTA
cCurrent at 1 μM 93-5
dCurrent at 1 μM ifenprodil
eThe GluN1-4a(Y109W) and GluN1-4a(H134A) mutants converted 93-series ligands into potentiators; EC50 value and maximal potentiation given
fCurrent at maximal ifenprodil potentiation
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2.0–2.5 × 106 cells mL−1, then infected with baculovirus. Sodium butyrate
was added to the infected cells to a ﬁnal concentration of 5 mM and culture
medium containing secreted GluN1a–GluN2B ATD fusion protein was harvested
96 h after infection.
Cells were removed from the medium by centrifugation and the clariﬁed
medium was concentrated and exchanged three times to cold TBS (200 mM NaCl,
20 mM Tris, pH 8.0) using tangential ﬂow ﬁltration with a molecular weight cutoff
of 30 kDa (Pall Corporation). The fusion protein was puriﬁed using metal afﬁnity
resin (GE Lifesciences) charged with CoCl2, and the eluted protein was dialyzed to
TBS with 40 mM imidazole overnight. The following day, glutathione in a 10:1
ratio, reduced:oxidized, was added to the dialyzed protein to a ﬁnal concentration
of 3 mM, along with EDTA, pH 8.0, to a ﬁnal concentration of 1 mM. Based on the
protein yield, a 1:100 ratio of TEV protease (mass:mass, TEV:ATD) was added to
the ATD solution and the reaction was incubated for 4 h at 18 °C. Next, EndoF1
endoglycosidase at a 1:5 ratio (mass:mass, EndoF1:ATD) was added to the ATD/
TEV mixture and dialyzed overnight at room temperature to 2 L TBS with 10%
glycerol and 20 mM imidazole.
The TEV digested, deglycosylated, dialyzed protein was subjected to a second
pass through a cobalt metal afﬁnity column to remove TEV, EndoF1, and the
fusion protein linker, and the runoff and washes using TBS with 20 mM imidazole
were collected until the OD280 reached zero. This sample was then dialyzed
overnight at 4 °C to 2 L TBS with 20% glycerol. Finally, the puriﬁed ATD
heterodimer was concentrated to 5 mgmL−1 (45 μM) and ﬂash-frozen in liquid
nitrogen, and then stored at −80 °C until needed.
Determination of ligand-binding afﬁnity by ITC. Puriﬁed GluN1a–GluN2B ATD
proteins from the above-described fusion protein puriﬁcation was dialyzed
extensively against a buffer containing 150 mM NaCl, 20 mM sodium phosphate,
and 5% glycerol. The ﬁnal pH of the solution was achieved using a ratio of dibasic:
monobasic sodium phosphate for pH values 6.5 and 7.6.
After dialysis, the protein sample was diluted to 10–15 μM and dimethyl
sulfoxide (DMSO) was added to a ﬁnal concentration of 1.5% (v/v), in order to
match that of the ligand solution. Ligands were dissolved in DMSO to a stock
concentration of 10 mM, and then further diluted to 150–200 μM using buffer from
the protein dialysis. The protein and ligand solutions were thoroughly degassed,
and the protein solution was placed in a 1.4 mL cell of a VP ITC calorimeter
(Malvern) with the experimental temperature set to 30 °C and differential power at
15 μCal s−1. The respective ligands were injected at 300 s intervals after an initial
delay of 180 s. Dilution enthalpy was calculated from post-saturation injections and
subtracted from total heats, and the data were ﬁt using a single-site model with the
program OriginLab 7.5.
Site-directed mutagenesis and TEVC recordings. Missense mutations were
introduced into rat cDNAs encoding GluN1-4a and GluN2B in the pGEM-HE
vector using the QuikChange protocol (Stratagene) using the primers listed in
Supplementary Table 2. These plasmids were then linearized with NotI and used as
templates for cRNA synthesis (Ambion). A total mass of 5–10 ng cRNA at a 1:2
weight ratio of GluN1-4a and GluN2B transcripts was co-injected into defollicu-
lated Xenopus laevis oocytes (EcoCyte Bioscience). The oocytes were incubated in
Barth’s solution containing 88 mM NaCl, 2.4 mM NaHCO3, 1 mM KCl, 0.33 mM
Ca(NO3)2, 0.41 mM CaCl2, 0.82 mM MgSO4, and 5 mM HEPES, at a ﬁnal pH of
7.4, supplemented with 0.1 mg mL−1 gentamicin sulfate, 1 μg mL−1 streptomycin,
and 1 UmL−1 penicillin at 15–19 °C. TEVC current recordings were performed
2–4 days after injection using an extracellular recording solution containing 90 mM
NaCl, 10 mM HEPES, 1 mM KCl, 0.5 mM BaCl2, and 0.01 mM EDTA at either pH
6.9 or pH 7.639. Voltage clamp was achieved and current responses were recorded
at a holding potential of –40 mV with a two-electrode voltage clamp ampliﬁer
(Warner) at room temperature (~23 °C). Currents were low-pass ﬁltered at 10 Hz
and digitized at 20 Hz by LabWindows/CVI (National Instruments). Maximal
effective concentrations of glutamate and glycine (100 and 30 μM, respectively)
were used in all recordings. Potency (IC50 values) for NMDA receptor inhibitors
were obtained by ﬁtting the concentration–response curves using
Response %ð Þ ¼ 100minimumð Þ= 1 modulator½ =IC50ð ÞnH
 þminimum;
ð1Þ
where IC50 is the concentration of modulator that generates a half-maximal effect,
nH is the Hill slope, and minimum is the degree of residual inhibition at a
saturating concentration of the NMDA receptor inhibitors.
Reporting Summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Data supporting the ﬁndings of this manuscript are available from the corre-
sponding author upon reasonable request. Atomic coordinates and structure fac-
tors have been deposited in the Protein Databank under accession codes 6E7R
(ATD heterodimer with 93-4), 6E7S (93-5), 6E7T (93-6), 6E7U (93-31), 6E7V (93-
88), 6E7W (93-97), and 6E7X (93-115). Source ﬁles for Figs. 1b, 4c–j, and 2, and
Supplementary Figures 1a, b and 7a–c are provided as a Source Data ﬁle.
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